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Abstract
Background: Pseudomonas aeruginosa is among the most common 
opportunistic hospital pathogens, which exhibit an innate resistance 
and has developed increasing resistance to many useful antimicrobial 
agents over the last decades. This study investigated the occurrence 
of important types of ESBLs and MBLs in association with potential 
important virulence factors among P. aeruginosa isolates from feces 
of Jordanian infants. 
Methods: A total of 302 feces samples were obtained randamely 
from neonates and infants admitted to Pediatric Clinic and the Neo-
nate Intensive Care Unit (NICU)/Jordan University Hospital (JUH), over 
a 9-month period of 2016-2017. Fecal samples were cultured for P. 
aeruginosa and their growth was identified and tested using micro-
biological and antibiotic susceptibility methods. Additionly, virulence 
factors, antimicrobial resistance genes and genotypes were detected 
using Polymerase Chain Reaction (PCR). 
Results: A total of 16/302 (5.3%) of P. aeruginosa isolates were 
recovered from feces samples of only hospitalized infants. Antimicro-
bial susceptibility of the isolates ranged between the lowest 18.7% 
to meropenem and highest of 87.5% to azetreonam among 9 tested 
drugs. The percentage of specific genes of ESBLs and MBLs in 16 P. 
aeruginosa isolates were the following: blaOXA-50, blaTEM, blaCTX-
M, blaVIM, blaKPC, blaSHV, blaGES, and blaVEB were detected at the 
rate of 13 (81.2%), 13 (81.2%), 12 (75%), 12 (75%), 11 (68.7%), 10 
(62.5%), 2 (12.5), 1 (6.2%), respectively. The percentage of the po-
tential virulence genes in the same isolates were detected as follow: 
lasB, algD, toxA, exoS and exoU at the rate of 100%, 87.5%, 81.2%, 
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Introduction
Pseudomonas aeruginosa is a major cause of no-
socomial infections in children and adults, and its 
responsible for about 10% of all hospital-acquired 
infections worldwide [1, 2]. 
P. aeruginosa causes severe infections especially 
in immune-compromised patients, and it continues 
to pose a therapeutic challenge resulting in high 
rate of morbidity and mortality due to development 
of drug resistance during antibiotic treatment of pa-
tients [3-4]. 
P. aeruginosa infections are becoming more diffi-
cult to treat, and the number of multidrug drug 
resistant isolates from clinical and hospital envi-
ronment sources is increasing worldwide including 
Arab Middle East countries [1, 5-7]. Recently, the 
most important issue is the emergence of carbap-
nemases in P. aeruginosa which considered as the 
last-line agents against Gram-negative bacteria in-
fections [8]. 
P. aeruginosa infections are especially difficult to 
prevent and to treat because of its common occu-
rrence in hospital environment and water sources, 
and for both intrinsic resistance to many antibiotics 
as well as rapid development of antibiotic resistance 
[9-11]. These features facilitate P. aeruginosa infec-
tions to become a serious health care issue in hos-
pitals worldwide [12].
P. aeruginosa is associated with presence and 
execration of large virulence factors that are in-
volved in various stages of the infection process 
allowing the organism to colonize any part of the 
infected host. These virulence factors include fla-
gellum, type IV pili, lipopolysaccharide, a type III 
secretion system, and alginate which are involved 
in the adhesion, motility and colonization [13-14]. 
In particular, P. aeruginosa is possessing cell-asso-
ciated and extracellular virulence factors controlled 
by a complex regulatory circuit involving cell-to-cell 
signaling (quorum sensing) system, allowing host-
pathogen interactions during infections [15]. The or-
ganism also releases several metabolites including 
mainly, exotoxins, exoproteases, heamolysins and 
pyocyanin or pyoverdin-fluorescein pigments. All 
these virulence factors are causing extensive tissue 
damage as well as facilitate bacterial multiplication 
and the spread in host tissues [5, 16]. 
The emergence of extended-spectrum-β-
lactamases (ESBLs) and metallo-β-lactamases (MBLs) 
compromised the effect of most β-lactam antibio-
81.2%, 31.2%, respectively. All P. aeruginosa isolates observed to 
develop beta-hemolysis on both human and sheep blood agar, and 
to produce either pyoverdin (56.3%) or pyocyanin (43.7%). 
Conclusions: The present study demonstrates high occurrence of 
multidrug resistant P. aeruginosa isolates from only hospitalized infant 
feces which also carried high rates of important genes of ESBLs and 
MBLs and potential virulence factors. 
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tics including carbapenems which are the drug of 
choice for treatment of infections of Gram-negative 
ESBL-producers [17-18]. Reports of carbapenem re-
sistant P. aeruginosa recovered from patients have 
been documented from different Arab regions, in-
cluding Jordan, Syria, Egypt, Saudi Arabia, Kuwait 
and Lebanon [5, 19-23]. 
This study aims to investigate the distribution of 
most important types of ESBLs, MBLs, and poten-
tial virulence genes in P. aeruginosa isolates from 
feces of examined infants in a tertiary care center 
in Amman, Jordan by using culture and molecular 
PCR methods.
Materials and Methods
This prospective study was randamly conducted at 
Jordan University Hospital (JUH) neonatal unit and 
at outpatient pediatric clinic over the period from 
May 2016 to February 2017, only one sample was 
collected from each patient.
 The study was approved by the IRB and ethi-
cal committee at JUH (2016/118). Informed consent 
was taken from parents before obtaining the fecal 
samples.
Neonates and infants up to one year old were 
included in the study. Neonates and infants with 
gastrointestinal anomalies and those whoes parents 
declined consent were excluded. Anal swabs were 
colleted by neonatal nurse or physician.
Medical charts of included infants were re-
viewed and their parents were interviewd using 
a structured data sheet. Demographic and clinical 
data in addition to current or recent antibiotics 
therapy within two weeks of the encounter were 
also documente.
Bacterial standard strains
The following bacterial standard strains were inclu-
ded as control: P. aeruginosa controls: ATCC 27853, 
ATCC 9027, and P. aeruginosa PAO1 strain had been 
used for quality control of antimicrobial susceptibili-
ty test and PCR detection of P. aeruginosa strains, 
and controls (CL 120 & CL 162, Universite´ Libanai-
se, Tripoli, Libanon, Prof. Monzer Hamze) that were 
positive for IMP-1, VIM-2, K. pneumonia (ATCC 
BAA-1705) positive for blaKPC and E. coli (ATCC 
51446) positive for blaCTX-M, and blaNDM-1).
Culture, isolation, identification 
All fresh collected fecal samples had been diluted in 
2 ml NaCl-saline (0.9%) and then inoculated onto 
Cetrimide Pseudomonas Selective Agar (Merck, 
Germany). 
All suspected growth of P. aeruginosa was iden-
tified as P. aeruginosa according to the following 
characteristics: positive oxidase test, growth at 42 
°C, negative lactose and glucose fermentation in 
tube of Kligler iron agar. Five colonies of P. aerugi-
nosa growth were subcultured into cetrimide agar 
to get pure culture of the organism and then a 
few colonies were inoculated and stored in cryotu-
bes containing brain-heart infusion broth with 20% 
glycerol at -70 ºC for further investigation and con-
firmation by PCR.
Antimicrobial susceptibility test using disc 
diffusion method 
Antimicrobial susceptibility test using disc diffusion 
method was performed according to the recom-
mendation of the Clinical Laboratory and Standards 
Institute (CLSI, 2015) [24]. 
Minimum inhibitory concentration (MIC) using 
E-test
All isolates of P. aeruginosa which were MDR to 
three or more antibiotic classes have their MICs 
measured by E-test for ceftazidime, amikacin, colis-
tin, and imipenem, and their results were interpre-
ted according to CLSI, 2015 [24].
DNA extraction and PCR procedure 
The bacterial DNA was extracted using the Wizard 
genomic DNA Purification Kit 
The InTernaTIonal arabIc Journal of anTImIcrobIal agenTs 
ISSN: 2174-9094
2019
Vol. 9 No. 2:4
doi: 10.3823/834
This article is available at: www.iajaa.org / www.medbrary.com 4
 (Promega, USA) according to manufactures ins-
tructions. Two PCR assays were performed; one 
is specific for the genus Pseudomonas, while the 
other is specific for P. aeruginosa. Two pairs of 
primers were used for each assay based on 16 
ribosomal DNA (rDNA) sequence. A positive con-
trol of P. aeruginosa ATCC 27853 and ATCC 9027 
were used for the identification of the specific se-
quences.
Plasmid extraction 
The bacterial plasmid was extracted using the EZ-10 
Spin Column Plasmid DNA- Minipreps Bio Basic kit 
(Canada) according to manufactures protocol. 
Confirmation of P. aeruginosa
All isolates were confirmed as P. aeruginosa using 
specific primers and PCR as shown in Table 1.
Table 1.  Primer targets, sequences and their product size for five ESBLs and virulenc genes among P. 
aeruginosa isolate.
Target Primer Primer sequence (5' to 3') Product size (bp) Ref.
Pseudomonas species PA-GS-F PA-GS-R
GACGGGTGAGTAATGCCTA 
CACTGGTGTTCCTTCCTATA 
618 25
P. aeruginosa PA-SS-F PA-SS-R
GGGGGATCTTCGGACCTCA 
TCCTTAGAGTGCCCACCCG 
956 25
blaCTX-M CTX-M (F) CTX-M (R)
CGCTTTGCGATGTGCAG 
ACCGCGATATCGTTGGT
550 26
blaVEB-1 VEB-1 (F) VEB-1 (R)
CGACTTCCATTTCCCGATGC 
GGACTCTGCAACAAATACGC 
642 27
blaIMP IMP-A IMB-B
GAAGGCGTTTATGTTCATAC 
GTACGTTTCAAGAGTGATGC 
587 28
blaVIM VIM2004A VIM2004B
GTTTGGTCGCATATCGCAAC 
AATGCGCAGCACCAGGATAG 
382 28
blaSHV-1 SHV-1 (F) SHV-1 (R)
TGGTTATGCGTTATATTCGCC 
GCTTAGCGTTGCCAGTGCT
867 29
blaGES-1 GES-1 (F) GES-1 (R)
ATGCGCTTCATTCACGCAC 
CTATTTGTCCGTGCTCAGG
864 30
blaKPC KPC (F) KPC (R)
ATGTCACTGTATCGCCGTCT 
TTACTGCCCGTTGACGCCC
880 31
blaOXA-50 OXA- (F) OXA- (R)
GAAAGGCACCTTCGTCCTCTAC 
CAGAAAGTGGGTCTGTTCCATC 
400 32
blaNDM-1 NDM-1 (F) NDM-1 (R)
GGTGCATGCCCGGTGAAATC 
GAGCACTTCTTTTGTGATGGC 
660 33
Tox A Tox A-F Tox A-R
CTGCGCGGGTCTATGTGCC 
GATGCTGGACGGGTCGAG
270 34
Las B Las B-F Las B-R
GGAATGAACGAAGCGTTCTCCGAC 
TTGGCGTCGACGAACACCTCG 
284 34
Alg D Alg D-F Alg D-R
CGTCTGCCGCGAGATCGGCT 
GACCTCGACGGTCTTGCGGA 
313 34
Exo S ExoS-F ExoS-R
CTTGAAGGGACTCGACAAGG 
TTCAGGTCCGCG TAGTGAAT 
504 15
ExoU ExoU-F ExoU-R
GGGAATACTTTCCGGGAAGTT 
CGATCTCGCTGCTAATGTGTT 
428 15
PilB PilB-F PilB-R
 ATGAACGACAGCATCCAACT 
GGGTGTT GACGCGAAAGTCGAT
826 15
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Detection of ESBLs, MBLs and virulenc genes 
All primers, sequences and their product size for 
detection of extended-spectrum-β-lactamases (ES-
BLs), metallo-β-lactamases (MBLs) and virulenc ge-
nes were used according to references (25-34) as 
shown in Table 1. 
Statistical analysis 
Data generated from the study were tabulated as 
Microsoft Excel sheet and Uploaded to Statistical 
Package for Social Sciences (SPPSS version 20), fre-
quency and percentage were calculated for the 
categorical data and Pearson’s chi-squared test or 
Fisher’s exact test were applied to determine po-
tential factors associated with P. aeruginosa and 
to determine whether there are any statistical di-
fferences between groups, the level of significance 
was set at a P value of 0.05 to test the hypothesis 
of no association. Fisher’s exact test replaces chi-
squared test when the minimum expected count 
is less than five.
Results
General demographic characteristics of all 302 exa-
mined infants which were divided in hospitalized 
and non-hospitalized infants are shown in Table 2. 
A total of 16/302 (5.3%) isolates were found to 
be positive for P. aeruginosa (Table 2). All positive 
P. aeruginosa isolates were found in hospitalized 
infants. The age range of the enrolled hospitalized 
infants being colonized with P. aeruginosa was (1-
27) days, about 10 (62.5%) positive colonization 
occurred in females (P = 0.026) which is significant, 
positive colonization with 
P. aeruginosa during the length of hospital stay 
had been taken into account, the mean length of 
hospital stay was 8.1 days (Table 2). All P. aerugino-
sa isolates were resistant to ciprofloxacin, norfloxa-
cin and imipenem (25%), followed by azetreonam 
(31%), meropenem (38%) piperacillin-tazobactam 
(44%9, ceftazidime and amikacin (56%) and gen-
tamicin (75%) (Table 3). The Minimum Inhibitory 
Concentration (MIC) range for four antibiotics are 
shown in Table 3, and none of the isolate was re-
sistant to colistin. 
The majority of fecal P. aeruginosa isolates were 
positive for the following virulence factors: Elasta-
seB (100%) and AlgD (87.5%), and slightly in less 
percentage (81.3%) for both extracellular protein 
toxins (exoenzymeS and exotoxinA) (Table 4). Both 
ExoenymeU and PilB protein were only positive 
in 61.3% and 6.3%, respectiviely. All 16 isolates 
showed pigmentation of pyoverdin (57.3%) or pyo-
cyanin (42.7%) and all produced beta-hemolysis on 
human and sheep blood in vitro (Table 5). Among 
the ESBLs, TEM was the most frequent enzyme 
found in (81%) in P. aeruginosa isolates, followed 
by CTX-M (75%), whereas the other types of VEB 
and GES were detected in the range of 6 % and 
13%, respectively. Both blaOXA-50 and KPC were 
found at 81% and 69%, respectively (Table 6). 
Table 2.  Major demographic characteristics of 302 
investigated infants.
Patients 
characteristics
hospitalized 
infants
Non 
-hospitalized 
infants P-Value
n % n %
Gender  
Males 104 60 66 51.1
0.006Females 69 40 63 48.9
Total 173 57.3 129 42.7
Age
1-29 days 170 98.3 43 33.3
< 0.001
1-12 months 3 1.7 86 66.7
Clinical situation
Presence of 
diarrhea
 0  37 28.7 < 0.001
Prior use of Antibiotics 
Treatment with 
Antibiotics 
61 35.3 34 26.4
0.049
No antibiotics 
treatment
112 64.7 95 73.6
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Table 4.  Distribution of virulence genes among 16 
P. aeruginosa isolates.
Virulence factor Gene
No. (%) Positive 
virulence genes
Elastase B las B 16  (100)
Alginate alg D 14  (87.5) 
Exotoxin A tox A 13  (81.3)
Exoenyme S exo s 13  (81.3)
Exoenyme U exo u 5  (31.3)
PilBprotein pil B 1  (6.3)
Pyoverdin* - 9  (57.3)
Pyocyanin* - 7  (42.7)
Beta-hemolysis** - 16 (100)
*: Recorded by presence the yellow-green color 
(pyoverdin) or blue-green color (pyocyanin) of isolates on 
Pseudomonas culture agar after 24-48 hr incubation
**: Detected by presence of complete hemolytic activity 
of isolat es on human and sheep blood agar plates after 
48 hr incubation
Table 5.  Distribution of ESBLs genes among 16 P. 
aeruginosa isolates. 
Virulence factor
P. aeruginosa isolates 
No. %
blaTEM 13 81
blaCTX-M 12 75
blaSHV-1 10 63
blaGES-1 2 13
blaVEB 1 6
blaKPC 11 69
blaOXA-50 13 81
blaVIM 12 75
bIaIMP Nil
blaNDM-1 Nil
Table 3.  Antimicrobial susceptibility pattern of 16 
P. aeruginosa isolates using diffusion disc 
amd MIC-Etest mehods.
Domains/Facets
Resistant MIC50 MIC90
MIC 
Range 
No. % µg/ml µg/ml µg/ml*
Ciprofloxacin 4 25 - - -
Imipenem 4 25 3.6 6.5 0.75-32
Aztreonam 5 31 - - -
Meropenem 6 38 - - -
Piperacillin-
tazobactam
7 44 - - -
Ceftazidime 9 56 1.92 3.45 0.50-12**
Amikacin 9 56 7.62 13.72 3-48
Gentamicin 12 75 - - -
Colistin - 0.18 0.32 0.50-1.2
*: Breakpoints for susceptible P. aeruginosa isolates (µg/ml) 
were the following: Amikacin; ≤ 8, Ceftazidime; 
≤ 8, Imipenem ≤ 4, Colistin; ≤ 2. 
**: Only 25% of isolates were resistant using Etest.
Discussion
Pseudomonas aeruginosa is accounting for 7.1% 
of all hospital infections in the United States ac-
cording to a recent study [35]. The organism is 
a frequent colonizer of intestinal tract of human, 
especially after prolonged antibiotic treatment or 
ICUs admission. Since P. aeruginosa is widely dis-
tributed in most hospital settings, the organism is 
often colonizing and infect hospitalized patients, 
particularly immune-compromised patients, pa-
tients with compromised lungs and burns as well 
as infants in neonatal intensive care units (NICU) 
[36, 39-40]. Previous studies have demonstrated 
that colonization of adults and children patients 
with P. aeruginosa can be associated with diarr-
hea or subsequent infection with the same strain 
of P. aeruginosa [36, 39-40]. Therefore, detection 
of patients in the ICUs colonized with P. aerugi-
nosa can be helpful to control hospital acquired 
infection and in selection of empiric antibiotics in 
suspected cases of sepsis [36]. 
The present study shows that 5.3% of P. aeru-
ginosa isolates were recovered from the fecal sam-
ples of hospitalized infants in (NICU), whereas all 
fecal samples obtained from non-hospitalized pa-
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tients were negative. The majority of these isolates 
(62.5%) was significantly found (P=0.006) in feces 
of hospitalized femal infant as shown in Table 2.
Recent studies reported that nosocomial out-
breaks caused by MDR P. aeruginosa are occurring 
around the world, and these outbreaks are fre-
quently caused by clones of
P. aeruginosa producing metallo-betalctamases 
(MBLs), mostly VIM and IMP types. These resistan-
ce markers can be acquired either by chromosomal 
mutations or horizontal gene transfer [41-42]. Neo-
natal infection with P. aeruginosa is mostly acqui-
red due to their underdeveloped immune system, 
especially when these infants are catheterized with 
intravascular catheters/devices and/or receiving pa-
renteral nutrition, [43-44]. Almost all P. aerugino-
sa isolates in this study were resistant for one or 
more commonly used antibiotics in treatment of 
Pseudomonas infections, especially to carbapenems 
(meropenem and impenem) (Table 3). This can be 
explained by the overexpression of efflux pumps 
that expel carbapenems and lead to carbapenem 
resistance [45]. However, all isolates were suscepti-
ble to colistin. 
The present study demonstrates that both OXA-
50 and TEM were the most frequent phenotypes 
found in P. aeruginosa isolates, followed by CTX-M, 
BlaVIM-2, whereas both blaIMP-15 and blaNDM-1 
were not detected in all isolates. These findings are 
in agreement with a recent published study on P. 
aeruginosa isolates from respiratory tract of Jorda-
nian patients [5]. 
The present study has detected that high per-
centage of our P. aeruginosa isolates (68.7%) were 
producers of KPC. This result should be conside-
red serious since KPC genes found often in asso-
ciation with transferable plasmids and transposons, 
and can result in a rapid spread of these genes 
in Gram-negative opportunistic pathogens [46-47]. 
However, it is important to note that NDM-1 type 
carbapenemase is not detected in any of the
P. aeruginosa isolates
The majority of our fecal P. aeruginosa isolates were 
positive for some of the most important virulence 
factors as presented by ElastaseB and AlgD, and 
slightly in less rate for both extracellular protein to-
xins, ExoenzymeS and ExotoxinA. A previous Jor-
danian study has also shown that P. aeruginosa 
isolates from respiratory tract sources were mostly 
producers of same virulence factors [5]. 
The majority of our P. aeruginosa isolates produ-
ced pigments, either pyoverdin or pyocyanin. The 
redox-active pigment pyocyanin is responsible for 
the blue-green color characteristics of P. aerugino-
sa, and it is also required to express cell fatal cyto-
toxicity, while pyoverdine is a siderophore involved 
in iron acquisition, participate in biofilm formation, 
and its chelating activity may contribute in develo-
ping antibiotics resistance [13, 19]. 
Conclusion
This study provides important epidemiological data 
on antimicrobial resistance profiles, distribution of 
ESBLs and MBLs and presence of virulence factors 
among fecal P. aeruginosa isolates from infants du-
ring their hospitalized.
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